Y-mAbs Therapeutics, Inc. (YMAB): Price and Financial Metrics


Y-mAbs Therapeutics, Inc. (YMAB)

Today's Latest Price: $37.50 USD

0.81 (2.21%)

Updated Sep 25 4:00pm

Add YMAB to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

YMAB Daily Price Range
YMAB 52-Week Price Range

YMAB Stock Price Chart Technical Analysis Charts


YMAB Price/Volume Stats

Current price $37.50 52-week high $50.49
Prev. close $36.69 52-week low $14.16
Day low $36.38 Volume 142,774
Day high $37.83 Avg. volume 211,497
50-day MA $39.68 Dividend yield N/A
200-day MA $35.29 Market Cap 1.50B

Y-mAbs Therapeutics, Inc. (YMAB) Company Bio


Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is based in New York, New York.


YMAB Latest News Stream


Event/Time News Detail
Loading, please wait...

YMAB Latest Social Stream


Loading social stream, please wait...

View Full YMAB Social Stream

Latest YMAB News From Around the Web

Below are the latest news stories about Y-mAbs Therapeutics Inc that investors may wish to consider to help them evaluate YMAB as an investment opportunity.

Y-mAbs Therapeutics (YMAB) Investor Presentation - Slideshow

The following slide deck was published by Y-mAbs Therapeutics, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 18, 2020

Y-mAbs Is One To Accumulate Before PDUFA

Y-mAbs Therapeutics, Inc. (YMAB) is interesting to me because despite being only in phase 2, it has two lead candidates, both running pivotal trials with just their phase 2 studies, one of which just submitted a rolling BLA and has a PDUFA date of November 30 under priority review, and...

Avisol Capital Partners on Seeking Alpha | August 17, 2020

Y-mAbs Announces Second Quarter 2020 Financial Results and Recent Corporate Developments

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter 2020. “We are very pleased with our second quarter 2020 financial results, especially seen in conjunction with the recent completion of our omburtamab BLA submission to the FDA. We are also very excited about the FDA’s acceptance of our naxitamab BLA for priority review, and the continued commercial ramp-up for our potential launch of both compounds in the U.S.,” stated Thomas Gad, Founder, Chairman and President.Dr. Claus Moller, Chief Executive Offi...

Yahoo | August 6, 2020

Y-mAbs Announces Completion of Submission of Omburtamab Biologics License Application to FDA

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that on August 5, 2020, the Company completed the submission of its Biologics License Application (“BLA”) under the FDA’s Rolling Review process for omburtamab. Omburtamab is an investigational, monoclonal antibody that targets B7-H3, an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types. The omburtamab BLA is for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. The submission is based on the safety and effica...

Yahoo | August 6, 2020

Y-mAbs Announces Data to be Presented at 2020 SIOP

NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, is pleased to announce the acceptance of five oral presentations at the International Society of Pediatric Oncology (“SIOP”) Virtual Annual Congress held October 14 through October 17, 2020 in Ottawa, Canada. The abstracts are publicly available online at https://siop-congress.org/scientific-programme/NaxitamabThe abstracts include the following presentations of naxitamab, one of the Company’s lead product candidates, which is currently being evaluated for the treatment of pediatric patients with relapsed o...

Yahoo | July 27, 2020

Read More 'YMAB' Stories Here

YMAB Price Returns

1-mo -10.42%
3-mo -17.89%
6-mo 43.68%
1-year 45.63%
3-year N/A
5-year N/A
YTD 20.00%
2019 53.64%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7904 seconds.